Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

MRKR

Marker Therapeutics (MRKR)

Marker Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MRKR
DateTimeSourceHeadlineSymbolCompany
08/28/20247:00AMGlobeNewswire Inc.Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsNASDAQ:MRKRMarker Therapeutics Inc
08/14/20243:47PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
08/14/20243:39PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
08/14/20243:30PMGlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
08/12/20246:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
08/12/20246:00AMGlobeNewswire Inc.Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s LymphomaNASDAQ:MRKRMarker Therapeutics Inc
06/12/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
05/17/20245:25PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MRKRMarker Therapeutics Inc
05/15/20243:40PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
05/15/20243:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
04/08/20246:00AMGlobeNewswire Inc.Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies NASDAQ:MRKRMarker Therapeutics Inc
03/25/20244:45PMGlobeNewswire Inc.Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
03/22/202411:30AMGlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:MRKRMarker Therapeutics Inc
03/01/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
02/26/20246:58AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
01/22/20246:30AMGlobeNewswire Inc.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601NASDAQ:MRKRMarker Therapeutics Inc
01/08/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
01/08/20247:24AMGlobeNewswire Inc.Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationNASDAQ:MRKRMarker Therapeutics Inc
12/21/202310:00AMGlobeNewswire Inc.Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”NASDAQ:MRKRMarker Therapeutics Inc
12/11/20236:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
12/11/20236:00AMGlobeNewswire Inc.Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
11/20/20233:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
11/09/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
11/09/20234:00PMGlobeNewswire Inc.Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
11/09/20233:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
09/11/20236:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
09/11/20236:00AMGlobeNewswire Inc.Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
08/30/20237:00AMGlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MRKRMarker Therapeutics Inc
08/14/20233:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
08/14/20233:30PMGlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:MRKRMarker Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRKR